Clinical Trial 24372

• Overview

  Study Title:

  Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

• Treatments

  Therapies:

  Immunotherapy; Radiotherapy; Selective inhibitor of VEGF

  Medications:

  Avelumab (); BMS-936558 (Nivolumab); Cabozantinib (XL 184); E7080 (Lenvatinib); Ipilimumab (); Lenvatinib (Lenvima); MSB00100718C (Avelumab); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Yervoy (Ipilimumab); axitinib (AG-013736)

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.